secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-06-10T23:59:59+00:00
Accession:  0001558370-25-008512
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics elects Dr. Akintunde Bello to Board of Directors
-------------------------------------------------------------------

- Board increased to ten directors; Dr. Bello elected as Class II director effective June 10, 2025.
- Term expires at 2026 annual meeting; appointed to Nominating and Corporate Governance Committee.
- Compensation follows standard non-employee director terms as described in the 2025 proxy statement.
- Dr. Bello will enter into the company's standard indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025008512/0001558370-25-008512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025008512/xlo-20250610x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer